DORA Insomnia Drugs: Australia’s New Sleep Medication Guidelines

Dual Orexin Receptor Antagonists: What Australia’s New Insomnia Guidelines Say

Six leading Australian health organizations — including the Australasian Sleep Association and the Royal Australian College of General Practitioners — have jointly published a position statement on managing adult insomnia, and it signals a shift in how medications are prescribed. Dual orexin receptor antagonists (DORAs), a newer class of sleep drugs, feature prominently alongside cognitive behavioral therapy for insomnia (CBT-I), while older sedatives face tighter caution.

How DORAs Work: Turning Down the Brain’s Wake Switch

Orexin (also called hypocretin) is a neuropeptide produced in a small cluster of neurons in the hypothalamus. During the day, these neurons fire steadily, stabilizing wakefulness and preventing dangerous lapses into sleep. In insomnia, the wake signal can remain too strong at night — the brain cannot fully “let go” of arousal.

DORAs block two orexin receptors, OX1R and OX2R, dampening that wake-promoting signal. The result is not forced sedation but a natural slide into sleep, orchestrated by the brain’s own sleep circuits in the ventrolateral preoptic nucleus and brainstem. This mechanism helps explain two clinically important differences from older drugs:

• No dependence signal: benzodiazepines potentiate GABA broadly, producing tolerance and withdrawal. Orexin antagonists leave GABA systems untouched.
• Physiological sleep architecture: DORAs preserve slow-wave sleep and REM proportion, whereas benzodiazepines suppress deep sleep.

For a deeper look at one drug in this class, see our coverage of lemborexant’s effects on sleep and eye movements.

What the Australian Position Statement Recommends

Published in Sleep Advances (2026) and authored by more than 30 clinicians and researchers led by Dr. Alexander Sweetman of the Australasian Sleep Association, the statement represents sleep physicians, GPs, psychologists, pharmacists, nurses, and people with lived experience. Its core message: insomnia is a treatable disorder, not a symptom to tolerate.

CBT-I remains the first-line treatment. But when medication is appropriate, the guideline points toward orexin receptor antagonists as a better-characterized option than long-term benzodiazepine or Z-drug use. DORAs such as daridorexant, lemborexant, and suvorexant show meaningful reductions in time to fall asleep and wake-after-sleep-onset, with trial evidence extending up to a year — as demonstrated in the vornorexant 52-week trial showing no rebound insomnia.

Honest caveats apply. DORAs can cause next-day sleepiness at higher doses, rare REM-related effects (cataplexy-like symptoms, complex sleep behaviors) have been reported, and cost limits access in many settings. Long-term comparative safety data, while growing, is still younger than for older drugs.

Why This Matters Beyond the Prescription Pad

The statement’s significance is partly cultural. Australian primary care has historically leaned on short-acting hypnotics, and the guideline explicitly encourages structured deprescribing. Notably, DORAs may assist this process: evidence shows they can help patients taper off benzodiazepines without losing sleep.

It also clarifies diagnosis. Chronic insomnia rarely exists alone — undetected sleep apnea, restless legs, anxiety, and poor sleep habits all change the treatment plan. A prescription without assessment risks masking a breathing disorder, a problem explored in our article on how apnea masquerades as other night-time complaints.

Practical Steps If You’re Considering a DORA

• Try CBT-I first. Digital and in-person programs deliver lasting benefit without medication, and combining both approaches is common.
• Get a proper assessment. Rule out sleep apnea and circadian disorders before blaming “just insomnia.”
• Time the dose correctly. DORAs are typically taken within 30 minutes of a consistent bedtime, not “when you feel like it.”
• Review at 3 months. Guidelines advise periodic reassessment rather than indefinite automatic repeats.
• Combine with behavioral levers. Morning light, fixed wake time, and limiting alcohol amplify any medication’s effect.

Frequently Asked Questions

Are DORAs safer than benzodiazepines for insomnia?

They carry a lower risk of dependence and withdrawal because they don’t act on GABA receptors, though individual side effects like next-day drowsiness still occur and long-term data remains newer.

How do dual orexin receptor antagonists make you sleepy?

They block orexin, a hypothalamic neuropeptide that maintains wakefulness, allowing the brain’s natural sleep-promoting circuits to take over.

Can I take a DORA long-term?

Trials up to 52 weeks, including vornorexant, show continued efficacy without rebound insomnia, but guidelines recommend periodic reassessment with your clinician.

Do DORAs help me stop taking sleeping pills?

Yes — emerging evidence suggests orexin antagonists can ease benzodiazepine tapering by controlling rebound insomnia during the transition.

Australia’s six-organization consensus gives patients and clinicians a clearer map: treat insomnia seriously, start with behavioral therapy, and when medication helps, orexin antagonists offer a mechanism that works with the sleeping brain rather than against it.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42781607/
https://pubmed.ncbi.nlm.nih.gov/42774912/
https://pubmed.ncbi.nlm.nih.gov/42769599/
https://pubmed.ncbi.nlm.nih.gov/42309189/
https://pubmed.ncbi.nlm.nih.gov/42274122/